相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial
Jing Huang et al.
CANCER MEDICINE (2021)
GPD1 Enhances the Anticancer Effects of Metformin by Synergistically Increasing Total Cellular Glycerol-3-Phosphate
Jianjiang Xie et al.
CANCER RESEARCH (2020)
Anlotinib as a molecular targeted therapy for tumors
Yi Gao et al.
ONCOLOGY LETTERS (2020)
Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation
Zengzhi Lian et al.
THORACIC CANCER (2020)
Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway
Haoyue Hu et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial
Jianhui Ma et al.
FRONTIERS IN ONCOLOGY (2020)
A phaseIIstudy of anlotinib in 45 patients with relapsed small cell lung cancer
Di Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade
Qian Yang et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma
Fei Song et al.
CELL DEATH & DISEASE (2020)
Reactive oxygen species mediate anlotinib-induced apoptosis via activation of endoplasmic reticulum stress in pancreatic cancer
Liguo Yang et al.
CELL DEATH & DISEASE (2020)
SYPL1 Inhibits Apoptosis in Pancreatic Ductal AdenocarcinomaviaSuppression of ROS-Induced ERK Activation
Yunda Song et al.
FRONTIERS IN ONCOLOGY (2020)
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Ai-Ping Zhou et al.
ONCOLOGIST (2019)
β-Thujaplicin induces autophagic cell death, apoptosis, and cell cycle arrest through ROS-mediated Akt and p38/ERK MAPK signaling in human hepatocellular carcinoma
Guangya Zhang et al.
CELL DEATH & DISEASE (2019)
Novel application of metformin combined with targeted drugs on anticancer treatment
Jun Deng et al.
CANCER SCIENCE (2019)
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma
Yihebali Chi et al.
CLINICAL CANCER RESEARCH (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Guoshuang Shen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer
Yongkun Sun et al.
THYROID (2018)
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial
Baohui Han et al.
JAMA ONCOLOGY (2018)
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study
Begoña Martin-Castillo et al.
Oncotarget (2018)
Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences
Eric Fontaine
FRONTIERS IN ENDOCRINOLOGY (2018)
Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Hazem I. Assi et al.
CANCER (2018)
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch et al.
LANCET (2017)
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers
Muhammad R. Khawaja et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Combinational strategies of metformin and chemotherapy in cancers
Hui-Hui Zhang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
Yongkun Sun et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator
Brandon Faubert et al.
CANCER LETTERS (2015)
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
Floris H. Groenendijk et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis
William W. Wheaton et al.
ELIFE (2014)
Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK
Y. Storozhuk et al.
BRITISH JOURNAL OF CANCER (2013)
Metformin Inhibits Growth of Thyroid Carcinoma Cells, Suppresses Self-Renewal of Derived Cancer Stem Cells, and Potentiates the Effect of Chemotherapeutic Agents
Guofang Chen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Understanding the benefit of metformin use in cancer treatment
Ryan J. O. Dowling et al.
BMC MEDICINE (2011)
Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling
Nahed El-Najjar et al.
APOPTOSIS (2010)
Redox-optimized ROS balance: A unifying hypothesis
M. A. Aon et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS (2010)
Metformin, Independent of AMPK, Inhibits mTORC1 in a Rag GTPase-Dependent Manner
Adem Kalender et al.
CELL METABOLISM (2010)
ERK and cell death: Mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence
Sebastien Cagnol et al.
FEBS JOURNAL (2010)
Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?
Issam Ben Sahra et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Simultaneous Induction of Non-Canonical Autophagy and Apoptosis in Cancer Cells by ROS-Dependent ERK and JNK Activation
Chew Hooi Wong et al.
PLOS ONE (2010)
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro
Irina N. Alimova et al.
CELL CYCLE (2009)
ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53
DM Tang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Requirement for ERK activation in cisplatin-induced apoptosis
XT Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
